Every 8-K that Recursion Pharmaceuticals, Inc. (RXRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow RXRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RXRX filings page.
Recursion Pharmaceuticals reported second-quarter 2026 results and highlighted major AI-driven pipeline and partnership progress. Total revenue was $7.7 million, primarily from collaborations, and net loss narrowed to $131.0 million. Research and development expense fell to $89.6 million and general and administrative expense to $41.5 million versus a year earlier.
Cash, cash equivalents and restricted cash were $556.8 million as of June 30, 2026, and the company now expects its cash runway to extend into early 2028. Net cash used in operating activities was $105.9 million for the quarter, while cash operating expense for the first half was $191.0 million; full-year 2026 cash operating expense guidance was reduced to under $375 million.
On the pipeline, Genentech exercised the first Validated Target Option in the neuroscience collaboration, advancing an unexplored target into early discovery. Internal programs advanced as REC-4881 for familial adenomatous polyposis generated additional Phase 2 data ahead of a November 2026 plenary presentation and ongoing FDA discussions, REC-7735 received IND clearance with a Phase 1/2 trial planned for the second half of 2026, and REC-1245 continued Phase 1 dose escalation with more data expected in the second half of 2026.
Recursion Pharmaceuticals, Inc. reported the results of its 2026 annual stockholder meeting held on June 17, 2026. Stockholders elected Class II directors Najat Khan, Ph.D., and Franziska Michor, Ph.D., to serve until the 2029 annual meeting or until successors are elected and qualified.
Stockholders also approved, on an advisory basis, the Company’s executive compensation, with 206,171,008 votes for, 30,893,147 against, and 1,280,852 abstentions, plus 126,675,762 broker non-votes. In addition, they ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026, with 361,743,500 votes for, 2,148,771 against, and 1,128,498 abstentions.
Recursion Pharmaceuticals, Inc. reported first-quarter 2026 revenue of $6.5 million, down from $14.7 million a year earlier, and a narrower net loss of $117.5 million versus $202.5 million. The company ended the quarter with $665.2 million in cash, cash equivalents and restricted cash and reiterated guidance for 2026 operational cash burn of less than $390 million, supporting runway into early 2028.
Operating efficiency improved, with research and development expenses falling to $87.9 million from $129.6 million and general and administrative expenses to $34.6 million from $54.7 million. Cash operating expense declined to $85.1 million from $120.2 million, driven by lower platform costs, improved efficiency and fewer one-time items.
The AI-driven pipeline advanced, including favorable early Phase 1 data for REC‑1245 showing it was well tolerated with no dose-limiting toxicities in 16 solid-tumor patients, strong Phase 2 efficacy signals for REC‑4881 in familial adenomatous polyposis with up to 53% median polyp reduction and 40% of patients improving in Spigelman stage, and first patient dosed in Phase 1 for REC‑4539, a brain-penetrant LSD1 inhibitor.
Recursion Pharmaceuticals announced a planned board transition involving its founder and current Chair, Chris Gibson, Ph.D. On April 28, 2026 he informed the company that he will not stand for re-election as a Class II director at the 2026 Annual Meeting of Stockholders.
The filing states his decision is not due to any disagreement with the company on operations, policies, or practices. Dr. Gibson will continue serving as Chair of the Board and on its committees through the end of his current term and will remain involved as a strategic advisor thereafter, supporting leadership continuity.
Recursion Pharmaceuticals is changing its top medical leadership. Vicki Goodman, M.D. will become Chief Medical Officer effective April 6, 2026, succeeding David Mauro, M.D., Ph.D., who will stay on as an advisor through May 29, 2026.
The company highlights Dr. Goodman’s more than two decades of oncology drug development experience, including senior roles at biotech and large pharmaceutical companies and prior service as an FDA medical officer. Management emphasizes her expertise in late-stage clinical development and regulatory strategy as Recursion advances its pipeline toward key clinical and regulatory milestones.
Recursion Pharmaceuticals reported strong 2025 revenue growth while remaining deeply loss‑making but well funded. Total revenue reached $74.7 million for 2025, up from $58.8 million, with fourth‑quarter revenue of $35.5 million versus $4.5 million a year earlier, largely from collaboration milestones with Roche/Genentech and Sanofi. The company ended 2025 with $753.9 million in cash, cash equivalents and restricted cash and expects its cash runway to extend into early 2028, after holding 2025 operating cash expense to about $399.2 million.
Net loss was $108.1 million in the fourth quarter, improving from a $178.9 million loss a year earlier, but full‑year net loss widened to $644.8 million from $463.7 million as R&D spending rose to $475.3 million, including data purchases and the Exscientia integration. Recursion highlighted its first AI‑enabled clinical proof of concept with REC‑4881 in familial adenomatous polyposis, advancing a diversified oncology and rare‑disease pipeline, and has earned more than $500 million in upfront and milestone payments across major partnerships.
Recursion Pharmaceuticals, Inc. furnished an updated investor presentation dated January 12, 2026. The presentation will be used at the JP Morgan Healthcare Conference and in other investor meetings, giving an overview of the company and its strategy. It is attached as Exhibit 99.1 to this report and is provided under Regulation FD, meaning it is being shared to keep all investors equally informed. The materials are expressly treated as "furnished" rather than "filed," which limits their exposure to certain Exchange Act liabilities and affects how they may be incorporated by reference into other regulatory documents.
Recursion Pharmaceuticals, Inc. filed a prospectus supplement to register for resale 7,088,742 Tempus Shares of its Class A common stock. These shares were issued to Tempus AI, Inc. as payment of annual license fees under a Master Agreement between the two companies.
The resale registration uses Recursion’s automatic shelf registration statement on Form S-3ASR and provides Tempus the ability to sell the shares in the public market. The company also filed a legal opinion from Wilson Sonsini Goodrich & Rosati, P.C. confirming the validity of these shares.
Recursion Pharmaceuticals (RXRX) announced leadership changes and furnished Q3 materials. The Board appointed Najat Khan, Ph.D. as Chief Executive Officer and President, effective January 1, 2026, and named Christopher Gibson, Ph.D. as Chair of the Board, effective the same date.
Dr. Khan’s compensation includes an annual base salary of $680,000, plus equity awards granted on November 5, 2025 of $500,000 in restricted stock units and $500,000 in stock options, each vesting over four years, and an additional equity award expected, subject to compensation committee approval, with an aggregate value of at least $7,500,000 (half RSUs, half options) vesting over four years. She will receive enhanced severance under the company’s plan, including vesting acceleration for awards that would have vested during the 12 months after a Non‑CIC Qualifying Termination.
Dr. Gibson will serve as Advisor to the CEO under a 12‑month agreement beginning January 1, 2026, with group health premiums paid for up to 12 months and continued vesting of prior equity awards subject to service. Robert Hershberg, M.D., Ph.D. was appointed Vice Chair and Lead Independent Director. The company furnished a Q3 press release and investor presentations as exhibits.
Recursion Pharmaceuticals (RXRX) reported that Roche exercised its option for Recursion’s Microglia Map, described as a first-of-its-kind whole genome map of the brain’s immune cells. Under their 2021 collaboration with Genentech, Inc. and F. Hoffmann-La Roche Ltd, Recursion will receive an Acceptance Fee of $30 million.
This milestone reflects progress within the Roche–Recursion collaboration and results in a cash inflow to Recursion tied to delivery of the Microglia Map under the agreement.
Recursion Pharmaceuticals amended its Form 8-K to report issuance and registration of contingent consideration tied to its ENPP1 JV acquisition. The company completed a GLP toxicology study milestone and on August 27, 2025 issued 2,397,023 Contingent Shares at a per-share price of $5.2148 (calculated from the $12,500,000 milestone). Earlier, on July 8, 2025 the company issued 1,457,952 Initial Shares as part of the Membership Interest Purchase Agreement that made ENPP1 JV an indirect wholly-owned subsidiary. Recursion also filed a prospectus supplement to register the 2,397,023 Contingent Shares for resale and attached a legal opinion from Wilson Sonsini regarding the legality of the shares.
Recursion Pharmaceuticals (RXRX) filed a Form 8-K dated 5 Aug 2025 to furnish its Q2-25 earnings press release and related investor materials. The filing triggers:
- Item 2.02 – Results of Operations & Financial Condition: Exhibit 99.1 contains the full press release covering quarter-end 30 Jun 2025.
- Item 7.01 – Regulation FD: Exhibits 99.2 and 99.3 provide an updated corporate deck and the presentation used during the same-day earnings call.
No financial metrics, guidance, or qualitative commentary appear in the body of the report; all substantive details reside in the furnished exhibits, which are explicitly not deemed “filed” under Exchange Act Section 18. The company remains listed on the Nasdaq Global Select Market under ticker RXRX. The document is principally procedural, confirming timely dissemination of earnings materials and incorporating the customary safe-harbor language that limits liability for furnished information.
On July 8, 2025, Recursion Pharmaceuticals, Inc. (RXRX) filed an 8-K announcing that its indirect subsidiary, Exscientia Ventures I, Inc., acquired the remaining 50% membership interest in RE Ventures I, LLC (ENPP1 JV) from Rallybio, turning the JV into an indirect wholly-owned subsidiary.
Key terms of the Membership Interest Purchase Agreement:
- Initial consideration: 1,457,952 Class A shares, valued at US$7.5 million (VWAP US$5.1442).
- Additional cash as specified in the agreement (undisclosed in the filing).
- Contingent consideration: up to US$12.5 million in additional Class A shares if ENPP1 development milestones are achieved.
- Share cap: Aggregate issuances under the agreement limited to 19.9% of total outstanding Class A + Class B shares; excess payments will be made in cash.
The equity was issued in a private placement relying on the Securities Act §4(a)(2) exemption. RXRX committed to file and maintain an SEC registration statement to facilitate the Seller’s resale of all issued shares. A prospectus supplement registering the resale of the initial 1.46 million shares was filed the same day (Form S-3ASR).
Investor take-away: The transaction consolidates full ownership of the ENPP1 asset while spreading additional payments over milestone achievements, preserving near-term liquidity. Dilution is controlled by the 19.9% cap, but shareholders face immediate issuance of 1.46 million shares and possible future cash/stock outflows tied to programme progress. No financial results were provided; forward-looking statements highlight development and regulatory risks.
Recursion Pharmaceuticals held its 2025 Annual Meeting on June 18, with stockholders voting on three key proposals. All proposals passed successfully.
Key outcomes include:
- Election of three Class I directors to serve until 2028: - Zachary Bogue (242.3M votes for) - Zavain Dar (203.3M votes for) - Robert Hershberg (233.5M votes for)
- Approval of executive compensation package with 239.9M votes in favor (97.4% of votes cast excluding abstentions)
- Ratification of PricewaterhouseCoopers LLP as independent auditor with 334.6M votes in favor (98.5% of votes cast excluding abstentions)
Notable was the significant support for Zachary Bogue and Robert Hershberg, while Zavain Dar received relatively more withheld votes. The executive compensation proposal received strong stockholder backing, demonstrating confidence in leadership compensation structures.